9.76
0.85 (9.54%)
| 前收盘价格 | 8.91 |
| 收盘价格 | 8.98 |
| 成交量 | 2,881,097 |
| 平均成交量 (3个月) | 1,383,291 |
| 市值 | 1,554,055,680 |
| 价格/销量 (P/S) | 14.72 |
| 股市价格/股市净资产 (P/B) | 10.19 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 |
| 营业毛利率 | -107.04% |
| 营业利益率 (TTM) | -542.82% |
| 稀释每股收益 (EPS TTM) | -0.750 |
| 季度收入增长率 (YOY) | -26.80% |
| 总债务/股东权益 (D/E MRQ) | 13.13% |
| 流动比率 (MRQ) | 2.95 |
| 营业现金流 (OCF TTM) | -180.63 M |
| 杠杆自由现金流 (LFCF TTM) | -133.93 M |
| 资产报酬率 (ROA TTM) | -30.02% |
| 股东权益报酬率 (ROE TTM) | -105.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Wave Life Sciences Ltd. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | 0.0 |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.70 |
|
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 16.25% |
| 机构持股比例 | 84.41% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 24.00 (Oppenheimer, 145.90%) | 购买 |
| 中 | 18.50 (89.55%) | |
| 低 | 14.00 (Raymond James, 43.44%) | 购买 |
| 平均值 | 18.67 (91.29%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 7.83 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Canaccord Genuity | 04 Aug 2025 | 19.00 (94.67%) | 购买 | 8.75 |
| Wells Fargo | 31 Jul 2025 | 21.00 (115.16%) | 购买 | 8.10 |
| Oppenheimer | 28 Jul 2025 | 24.00 (145.90%) | 购买 | 8.18 |
| Citigroup | 16 Jul 2025 | 16.00 (63.93%) | 购买 | 7.82 |
| Wedbush | 23 Jun 2025 | 18.00 (84.43%) | 购买 | 6.96 |
| Raymond James | 11 Jun 2025 | 14.00 (43.44%) | 购买 | 7.19 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CORRIGAN MARK | 8.11 | - | 12,700 | 102,997 |
| HENRY CHRISTIAN O | 8.11 | 8.76 | 3,030 | 18,288 |
| RA CAPITAL MANAGEMENT, L.P. | 8.11 | - | 12,700 | 102,997 |
| RAWCLIFFE ADRIAN | 8.11 | - | 12,700 | 102,997 |
| TAKANASHI KEN | 8.11 | 8.84 | 7,828 | 59,929 |
| TAN AIK NA | 8.11 | 8.84 | 24,273 | 196,031 |
| VERDINE GREGORY L. | 8.11 | - | 12,700 | 102,997 |
| WAGNER HEIDI L | 8.11 | - | 12,700 | 102,997 |
| 累积净数量 | 98,631 | |||
| 累积净值 ($) | 789,233 | |||
| 累积平均购买 ($) | 8.11 | |||
| 累积平均卖出 ($) | 8.81 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HENRY CHRISTIAN O | 董事 | 13 Aug 2025 | 自动卖出 (-) | 9,670 | 8.76 | 84,709 |
| HENRY CHRISTIAN O | 董事 | 11 Aug 2025 | 获得 (+) | 12,700 | 8.11 | 102,997 |
| TAN AIK NA | 董事 | 11 Aug 2025 | 获得 (+) | 25,400 | 8.11 | 205,994 |
| VERDINE GREGORY L. | 董事 | 11 Aug 2025 | 获得 (+) | 12,700 | 8.11 | 102,997 |
| RAWCLIFFE ADRIAN | 董事 | 11 Aug 2025 | 获得 (+) | 12,700 | 8.11 | 102,997 |
| TAKANASHI KEN | 董事 | 11 Aug 2025 | 获得 (+) | 12,700 | 8.11 | 102,997 |
| WAGNER HEIDI L | 董事 | 11 Aug 2025 | 获得 (+) | 12,700 | 8.11 | 102,997 |
| CORRIGAN MARK | 董事 | 11 Aug 2025 | 获得 (+) | 12,700 | 8.11 | 102,997 |
| RA CAPITAL MANAGEMENT, L.P. | 董事 | 11 Aug 2025 | 获得 (+) | 12,700 | 8.11 | 102,997 |
| TAN AIK NA | 董事 | 05 Aug 2025 | 自动卖出 (-) | 1,127 | 8.84 | 9,963 |
| TAKANASHI KEN | 董事 | 05 Aug 2025 | 自动卖出 (-) | 4,872 | 8.84 | 43,068 |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合